NEW YORK, Sept. 15, 2014 (GLOBE NEWSWIRE) -- Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased EDAP TMS S.A. ("EDAP" or the "Company") EDAP common stock between February 1, 2013 and July 30, 2014.
For more information, click here: http://zlk.9nl.com/edap-tms-edap.
The complaint alleges that during the Class Period the Company made false and/or misleading statements regarding its Ablatherm-HIFU device. In particular it is alleged that the Company made false and/or misleading statements and/or failed to disclose that: (a) the Company overstated the efficacy and safety of its Ablatherm trials by relying on cross-study comparisons rather than a head-to-head trial; (b) the study's survival endpoint was inappropriate for the patient populations; and (c) as a result of the aforementioned, the Company's statements regarding its business and operations were materially false and misleading at all relevant times.
On July 30, 2014, the FDA announced that a panel found EDAP had failed to demonstrate the efficacy of its product or that the benefits of the device outweighed its risks.
If you suffered a loss in EDAP you have until October 3, 2014 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/edap-tms-edap.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm's 26 attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.